Clinical Trial: NRG BR003

NRG BR003

Status: Closed

NCT#02488967

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

BR003 is closed to accrual effective April 22, 2022, at 5pm ET.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Available Clinical Trials

Clinical Trial: NRG BR003

NRG BR003

NCT#02488967

Navigation

About Us

Contact Us